Clinico-pharmacological characteristics of opioid drug-drug interactions in cancer patients with chronic pain syndrome

The aim of the review was to analyze published studies on the impact of opioid drug-drug interactions on the choice of analgesic therapy regimens.

Material and methods. A systematic literature search was conducted using PubMed, Scopus, Web of Science, and E-library databases.

Results. The review showed a clinical significance of pharmacokinetic interactions of opioids with other drugs in cancer pain treatment. The problems of individual choice of analgesics from different groups under conditions of co-morbidity and concomitant medication were discussed to ensure the effectiveness/safety of the treatment strategy affecting the quality of life of cancer patients.

Conclusion. A comprehensive assessment of factors in patients receiving opioid analgesics is a predictor of effective and safe analgesic therapy.

1. SummersK.H., Puenpatom RA., RajanN., Ben-JosephR., OhsfeldtR. Economic impact of potential drug - drug interactions in opioid analgesics. J Med Econ. 2011; 14 (4): 390-96. doi: 10.3111/13696998.2011.

2. van Leeuwen R.W.F., SwartE.L., Boven E., Boom F.A., Schuiten-makerM.G., Hugtenburg J.G. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011 Oct; 22 (10): 2334-41. doi: 10.1093/annonc/mdq761.

3. Buajordet I., Ebbesen J., Erikssen J., Br0rs O., Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001; 250: 327-341.

4. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J Clin. 2014 Jan-Feb; 64 (1): 9-29. doi: 10.3322/caac.21208.

5. Kapur B.M., Lala P.K., Shaw J.L. Pharmacogenetics of chronic pain management. Clin Biochem. 2014 Sep; 47 (13-14): 1169-87. doi: 10.1016/j.clinbiochem.2014.05.065.

6. Overholser B.R., Foster D.R. Opioid pharmacokinetic drug - drug interactions. Am J Manag Care. 2011 Sep;17 Suppl 11: S276-87.

7. CavallariL.H., Jeong H., Bress A. Role of cytochrome P450 geno-typeinthe steps toward personalized drug therapy. Pharmgenomics Pers Med. 2011; 4: 123-36. doi: 10.2147/PGPM.S15497.

8. Gudin J. Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec; 44 (6 Suppl): S4-14. doi: 10.1016/j.jpainsymman.2012.08.013.

9. Mercadante S., Porzio G., AielliF, Adile C., VernaL., Ficorella C., Giarratano A., Casuccio A. Opioid switching from and to tapen-tadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013 Jun; 29 (6): 661-6. doi: 10.1185/03007995.2013.791617.

10. Bobrova O.P., Dyhno YA., Shnayder NA., PetrovaM.M., Zyryanov S.K. Pharmacokinetic and pharmacogenetic aspects of personalized analgetic therapy with fentanil TTS in clinical oncology. Siberian journal of oncology. 2018; 17 (3): 94-100. (in Russian). doi: 10.21294/1814-4861-2018-17-3-94-100.

11. BernardSA., BrueraE. Drug interactions in palliative care. J. Clin. Oncol. 2000; 18 (8): 1780-1799. doi: 10.1200/JCO.2000.18.8.1780

12. SmithH.S. Opioid metabolism. Mayo Clin Proc. 2009 Jul; 84 (7): 613-24. doi: 10.1016/S0025-6196(11)60750-7.

13. Samer C.F., Lorenzini K. Ing, Rollason V, Daali Y., Desmeules JA. Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther. 2013 Jun; 17 (3): 165-84. doi: 10.1007/s40291-013-0028-5.

14. MadadiP.,HildebrandsD., GongI.Y., Schwarz U.I., Ciszkowski C., Ross C.J., Sistonen J., Carleton B.C., Hayden M.R., Lauwers A.E., Koren G. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics. 2010 Oct; 126 (4): e986-9. doi: 10.1542/peds.2009-1907.

15. Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., RebsamenM.C., RossierM.F., Hochstrasser D., Dayer P., J.A. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun; 160 (4): 907-18. doi: 10.1111/j.1476-5381.2010.00673.x.

16. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352: 2211-21. doi:10.1056/NEJMra032424.

17. DonatoM.T., MonteroS., CastellJ.V, Gomez-LechonM.J.,Lahoz A. Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal Bioanal Chem. 2010 Mar; 396 (6): 2251-63. doi: 10.1007/s00216-009-3441-1.

18. Chen C., Upward J., Arumugham T., Stier B., Davy M. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. Clin Ther. 2015 Feb 1; 37 (2): 349-57. doi: 10.1016/j.clinthera.2014.10.015.

19. Foursa O.O., Kozlovsky VL. The role of cytochrome p450-dependent biotransformation in metabolism of antipsychotics. Russian Society of Psychiatrists. 2013; 23 (4): 51-55. (in Russian).

20. Tekes K., Hashemi F, Szegi P, Sotonyi P, Laufer R., Kalasz H. Prodrugs and active metabolites among antidepressive compounds. Neu-ropsychopharmacol Hung. 2011 Jun; 13 (2): 103-10.

21. Alfaro C.L., Lam Y.W., Simpson J., Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000 Jan; 40 (1): 58-66.

22. Parker R.B., Soberman J.E. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy. 2011 Jul; 31 (7): 630-41. doi: 10.1592/phco.31.7.630.

23. Donato M.T., Hallifax D., Picazo L., Castell J.V, Houston J.B., Gomez-Lechon M.J., Lahoz A. Metabolite formation kineticsand intrinsic clearance of phenacetin, tolbutamide, alprazolam and midazolam in adenoviral P450 transfected HepG2 cells, and comparison with hepatocytes and in vivo. Drug Metab Dispos. 2010 Sep; 38 (9): 1449-55. doi: 10.1124/dmd.110.033605.

24. Pergolizzi J.VJr., Ma L., Foster D.R., Overholser B.R., Sowin-ski K.M., Taylor R.Jr., Summers K.H. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Pharm. 2014; 20 (5): 467-76. doi: 10.18553/jmcp.2014.20.5.467.

25. FengX.Q., Zhu L.L., Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017; 10: 1225-39. doi: 10.2147/JPR.S138698.ecollection 2017.

26. HanleyM.J., CancalonP, Widmer W.W., GreenblattDJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011 Mar; 7 (3): 267-86. doi: 10.1517/17425255.2011.553189.

27. Madlensky L., Natarajan L., Tchu S., Pu M., Mortimer J., Flatt S. W., Nikoloff DM., Hillman G., Fontecha M.R., Lawrence H.J., Parker B.A., Wu A.H., Pierce J.P. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May; 89 (5): 718-25. doi: 10.1038/clpt.2011.32.

28. Fihlman M., Hemmila T., Hagelberg N.M., Kuusniemi K., Back-man J.T., Laitila J., Laine K., Neuvonen P.J., Olkkola K.T., Saari T. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol. 2016; 72 (11): 1363-1371. doi: 10.1007/ s00228-016-2109-y.

29. Ziesenitz VC., Konig S.K., Mahlke N.S., Skopp G., Haefeli W.E., Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015; 55 (6): 708-717. doi: 10.1002/jcph.469.

30. Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., RebsamenM.C., Rossier M.F., Hochstrasser D., Dayer P, Desmeules J.A. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun; 160 (4): 907-18. doi: 10.1111/j.1476-5381.2010.00673.x.

31. Trobec K., Kerec Kos M., von Haehling S., Springer J., Anker S.D., Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 2013 Nov 8; 8 (П): e79603. doi: 10.1371/journal.pone.0079603.